Answers are grounded in this paper and cite their sources.
Subcutaneous daratumumab may be an effective treatment for cABMR; larger randomized trials are warranted to study its role in the treatment for cABMR in KTRs. dd-cfDNA may be a useful monitoring tool to predict and detect relapses.
No takes yet. Share an insight, caveat, or question.
Lye et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: